Peer-Reviewed Publications

    Deriving Protein Binding-Corrected Chemical Concentrations for In Vitro Testing

    Kolli, A. R.

    Published
    Aug 21, 2023
    DOI
    10.1111/cts.13616
    PMID
    37605430
    Link to publication
    Summary

    Extracellular chemical concentrations are considered physiologically relevant for in vitro testing and are evaluated in traditional in vitro systems using cell culture media containing 5–10% fetal bovine serum (FBS). However, depending on the physicochemical properties, and in vitro testing conditions, cells could be exposed to variable unbound extracellular concentrations. If in vitro unbound concentrations are not calculated, it is challenging to distinguish the chemical potency and concentration-driven responses. In this study, one- and two-protein binding models were used to estimate protein binding corrected chemical concentrations of various chemicals for in vitro testing. As ceftizoxime, moxifloxacin and nicotine have low protein binding affinity, the in vitro protein binding for 5-10% FBS is <5% and can be considered negligible. However, protein binding of moderate and highly protein-bound chemicals must be corrected for as the in vitro unbound concentrations in 5-10% FBS containing cell culture media will vary over a range of chemical concentrations. In vitro pharmacological and toxicological assessments must incorporate protein binding-adjusted in vitro concentrations to ensure physiologically relevant exposures. A user-friendly Excel spreadsheet is provided to help bench scientists calculate protein binding-corrected chemical concentrations for in vitro testing.

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Assessment of the Effects of Acute and Continuous Exposure to Tobacco Heating System 2.4 and Cigarette Smoke Total Particulate Matter on a Direct 2D Osteoblast/Osteoclast Coculture Model

    Pre-clinical Toxicology;Systems Toxicology

    Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

    Clinical

    Decreased smoking-attributable deaths in Germany with smoke-free products and tobacco control measures: a modeling study

    Smoke-free products

    Estimated public health impact of Italian smokers switching to smoke-free products: a population health impact modeling study

    Smoke-free products

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.